Rhenman & Partners Asset Management AB Sells 171,909 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Rhenman & Partners Asset Management AB lowered its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 46.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 195,591 shares of the company's stock after selling 171,909 shares during the quarter. Rhenman & Partners Asset Management AB owned about 0.16% of Apellis Pharmaceuticals worth $6,241,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of APLS. EverSource Wealth Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after buying an additional 758 shares during the last quarter. Signaturefd LLC lifted its position in shares of Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after acquiring an additional 918 shares during the period. US Bancorp DE grew its holdings in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock worth $103,000 after purchasing an additional 1,327 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $206,000. Finally, M&T Bank Corp acquired a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at $216,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Cedric Francois sold 13,551 shares of the business's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $412,356.93. Following the completion of the transaction, the chief executive officer now directly owns 418,519 shares in the company, valued at approximately $12,735,533.17. The trade was a 3.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $62,279.00. Following the completion of the sale, the chief financial officer now owns 88,100 shares in the company, valued at $2,528,470. This represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,238 shares of company stock valued at $1,857,510 over the last ninety days. Insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Trading Down 7.2 %

APLS traded down $1.41 during mid-day trading on Thursday, reaching $18.20. The stock had a trading volume of 845,091 shares, compared to its average volume of 2,117,785. The stock has a market capitalization of $2.28 billion, a P/E ratio of -8.91 and a beta of 0.85. Apellis Pharmaceuticals, Inc. has a 52 week low of $17.48 and a 52 week high of $57.85. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm's fifty day simple moving average is $25.19 and its two-hundred day simple moving average is $28.52.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. During the same period last year, the company earned ($0.73) earnings per share. The company's revenue was up 45.2% on a year-over-year basis. On average, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on APLS. HC Wainwright reissued a "buy" rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Scotiabank increased their price target on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a "sector perform" rating in a research report on Wednesday, April 2nd. Wedbush decreased their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Royal Bank of Canada dropped their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating for the company in a report on Monday, March 3rd. Finally, The Goldman Sachs Group decreased their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $45.59.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).